Clinical Trial Detail

NCT ID NCT02437136
Title Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Syndax Pharmaceuticals
Indications

melanoma

lung non-small cell carcinoma

Therapies

Entinostat + Pembrolizumab

Age Groups: adult

No variant requirements are available.